GURU.Markets stock price, segment price, and overall market index valuation
The company's share price C4 Therapeutics Inc.
C4 Therapeutics is a biotech company pioneering targeted protein degradation. Its stock price represents a venture bet on a revolutionary new treatment technology. The stock price reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Oncology targeted therapy
C4 Therapeutics (CCCC) is a biopharmaceutical company developing a new class of drugs called protein degraders (PROTACs) to target cancer-causing proteins. We classify this company as "Targeted Oncotherapy." The chart below shows the dynamics in this cutting-edge oncology sector.
Broad Market Index - GURU.Markets
C4 Therapeutics is a biotech company developing a new class of drugs (protein degraders) for the targeted destruction of cancer-causing proteins. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how C4 compares to it.
Change in the price of a company, segment, and market as a whole per day
CCCC - Daily change in the company's share price C4 Therapeutics Inc.
Shares of C4, an oncology company, are highly volatile. Change_co measures market reaction to preclinical and clinical trial data. This metric is an essential component for building valuation models for companies at the forefront of targeted therapy on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
C4 Therapeutics, Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. A comparison with CCCC's performance, with its protein degradation platform, helps to assess it as a high-risk, clinical-data-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
C4 is a biopharmaceutical company, a pioneer in the field of targeted protein cleavage. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with C4's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization C4 Therapeutics Inc.
For C4 Therapeutics, Inc., the year-over-year trend is a story of developing a new class of drugs—protein degraders (PROTACs). Its 12-month market cap is entirely dependent on progress in early clinical trials. Each successful step confirms the potential of its TORPEDO platform for targeted cancer drug development.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
C4 Therapeutics, Inc. is a biotech company pioneering the development of a new class of drugs that exploit protein degradation mechanisms. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
C4 Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization C4 Therapeutics Inc.
The price of C4, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its oncology drugs based on protein degradation technology, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs that utilize the body's natural system to "destroy" disease-causing proteins. The chart below reflects the current state of the art in the targeted oncology sector, where C4 offers a fundamentally new approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
C4 Therapeutics, Inc. is a biotech company developing a new class of drugs (protein degradation) for the treatment of cancer. Its shares are a venture bet on the success of this new technology. Its performance depends entirely on scientific data and news about clinical trials, rather than on general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization C4 Therapeutics Inc.
Shares of C4 Therapeutics, a biopharmaceutical company developing a new class of drugs (protein degradation), are extremely volatile. Weekly price movements depend entirely on news about the progress of preclinical and clinical trials. The chart below illustrates how short-term scientific events shape the value of the drug at the forefront of oncology.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
How does C4 Therapeutics' performance compare to the broader biotech sector? This chart compares the weekly stock price movements of this company, which is developing a new class of drugs, to the overall trend. This helps us understand whether its movement is the result of a unique scientific breakthrough or a reflection of overall investor sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
C4 Therapeutics is developing a new class of drugs that "destroy" cancer-causing proteins. This chart shows how disconnected its weekly performance is from the market. Share price movements are driven by news about the progress of its unique technology and clinical trial results, not by macroeconomics.
Market capitalization of the company, segment and market as a whole
CCCC - Market capitalization of the company C4 Therapeutics Inc.
C4 Therapeutics, Inc.'s market cap is a bet on its cutting-edge protein degradation platform for cancer drug development. This clinical-stage biotech company's valuation depends on the success of its new approach to targeted therapy. The chart shows how investors view this innovative, yet risky, scientific method.
CCCC - Share of the company's market capitalization C4 Therapeutics Inc. within the market segment - Oncology targeted therapy
C4 Therapeutics, Inc. is a biotechnology company pioneering targeted protein degradation. Its market share reflects the potential of its TORPEDO platform for developing a new class of cancer drugs.
Market capitalization of the market segment - Oncology targeted therapy
Here's a chart of the total market capitalization of biotech companies developing targeted protein degradation (TPD) technology. C4 Therapeutics is one of the pioneers in this revolutionary field. The chart shows how the market is valuing this new approach to drug development, which has the potential to treat previously inaccessible targets.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market valuation of a new approach to drug discovery. C4 Therapeutics' market cap is based on its protein degradation platform, which can combat previously inaccessible cellular targets. The line shows how breakthrough science is shaping its potential stake in the future of oncology.
Book value capitalization of the company, segment and market as a whole
CCCC - Book value capitalization of the company C4 Therapeutics Inc.
C4 Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its unique TORPEDO® platform for creating degradative drugs that target cancer-causing proteins. The pipeline's growth signals advances in research, which is the biotech company's core asset.
CCCC - Share of the company's book capitalization C4 Therapeutics Inc. within the market segment - Oncology targeted therapy
C4 Therapeutics's resources are not factories, but cutting-edge laboratories for the discovery and development of a new class of drugs that exploit protein degradation mechanisms. The chart reflects its share of this unique scientific infrastructure, which forms the physical basis for a new approach to cancer treatment.
Market segment balance sheet capitalization - Oncology targeted therapy
Below you can see the overall book value of the biotech sector. Compared to this, C4 Therapeutics, which is developing a new class of drugs (degraders), looks like a "lightweight." Its value lies in its unique scientific platform, not in the manufacturing facilities that have yet to be built.
Book value of all companies included in the broad market index - GURU.Markets
C4 Therapeutics is a biotech company developing a new class of drugs that destroy, rather than block, disease-causing proteins. The company's assets are their scientific platform and development pipeline. Their balance sheet is the value of a "molecular shredder" for diseases. Against the backdrop of the material world, they create its "cleaner."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - C4 Therapeutics Inc.
C4 Therapeutics' balance sheet is its cash and scientific platform. Its market capitalization is a bet on the success of its protein-degradation technology. The MvsBCap_Co chart shows how many times the "dream" of a new cancer treatment is worth compared to the company's cash in hand.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new class of drugs that "destroy" disease-causing proteins. Its value lies in its scientific platform. The chart shows the high speculative valuation of its innovative approach to drug development.
Market to book capitalization ratio for the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs that utilize the body's natural system to "destroy" disease-causing proteins. Its value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches to drug development, particularly in oncology.
Debts of the company, segment and market as a whole
CCCC - Company debts C4 Therapeutics Inc.
C4 Therapeutics, a biotech company developing a new class of drugs (protein degradation), uses debt to finance its innovative platform. This chart shows how the company raises capital to conduct preclinical and early clinical trials. In this cutting-edge field of science, debt is an investment in a completely new approach to treating diseases.
Market segment debts - Oncology targeted therapy
C4 Therapeutics is a pioneer in developing a new class of drugs called "protein degraders" for the treatment of cancer. This is a cutting-edge scientific field that requires significant funding. This chart shows how the clinical-stage biotech company is managing its resources to advance its innovative platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio C4 Therapeutics Inc.
C4 Therapeutics is a biotech company developing a new class of targeted cancer therapy drugs. This chart shows its reliance on debt to fund cutting-edge research. For a company at the forefront of science, debt is a huge risk, as financial sustainability depends entirely on the success of its innovative platform.
Market segment debt to market segment book capitalization - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new class of drugs that utilize the body's natural system to destroy disease-causing proteins. This is cutting-edge science. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
C4 Therapeutics (CCCC) is a biotech company developing a new class of drugs that utilize the body's own mechanisms to destroy disease-causing proteins. This chart shows the overall level of debt in the economy. It clearly demonstrates why cutting-edge companies like CCCC are almost always financed through equity.
P/E of the company, segment and market as a whole
P/E - C4 Therapeutics Inc.
This chart for C4 Therapeutics, a biotech developing a new class of drugs (protein degradation), is a measure of faith in its scientific platform. There is no P/E ratio. The company's valuation is based on the potential of its technology to create drugs for previously considered incurable targets, not on current revenue.
P/E of the market segment - Oncology targeted therapy
This chart shows the average P/E ratio for biotech companies. For C4 Therapeutics, which is working in the novel field of protein degradation, it serves as a backdrop. It reflects the overall level of investor faith in breakthrough oncology technologies, providing context for C4's valuation, which is a bet on its unique scientific platform.
P/E of the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs called "degraders," which harness the body's natural defenses to destroy disease-causing proteins. This risk appetite chart helps understand how investors evaluate cutting-edge and innovative therapeutic platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company C4 Therapeutics Inc.
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs called "protein degraders." This approach aims to destroy cancer-causing proteins, rather than simply blocking them. This graph reflects the expectations for this cutting-edge technology. The evaluation is entirely dependent on the success of its drugs in clinical trials.
%20P%2FE%20C4%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-C4-Therapeutics-Inc.&v=1772619725851 "Chart of the company's future (projected) P/E C4 Therapeutics Inc.")
Future (projected) P/E of the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new class of drugs—protein degraders—for the treatment of cancer. This chart reflects the company's long-term profitability expectations. It shows how highly the market values the potential of their innovative scientific platform for creating next-generation targeted therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772619725871 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs that "destroy" cancer-causing proteins. It is a cutting-edge scientific platform. This market expectations chart reflects investor willingness to fund fundamental scientific research with high risk but enormous potential for medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619725934 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit C4 Therapeutics Inc.
C4 Therapeutics is a biotech company developing a new class of drugs that utilize the body's natural system to "destroy" cancer-causing proteins. This technology is currently in clinical trials. Its financial performance reflects its investment in this breakthrough scientific platform.
Profit of companies in the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new class of drugs (protein degradation) for cancer treatment. The technology is cutting-edge, but still in its early stages. This chart reflects how scientific innovation is shaping the future of pharmaceuticals. The current losses of such companies are investments in platforms that could become the basis for a whole new class of drugs.
Overall market profit
C4 Therapeutics is a biotech company developing a new class of drugs (protein degradation) for the treatment of cancer. This is cutting-edge science. The company's success depends solely on the results of clinical trials and the potential of its platform. Its history is not tied to macroeconomic trends, which can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company C4 Therapeutics Inc.
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs called protein degraders for the treatment of cancer. This timeline reflects expectations, which are entirely dependent on the progress of its platform and clinical trials. The success of this new therapeutic approach could dramatically change the outlook.
%20profit%20of%20the%20company%20C4%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-C4-Therapeutics-Inc.&v=1772619726046 "Graph of future (projected) profit of the company C4 Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new class of drugs called degraders for targeted cancer therapy. This chart shows the revenue forecast for the targeted oncotherapy sector. It reflects expectations for breakthroughs in cancer treatment at the molecular level. This backdrop is important for assessing the potential of C4 Therapeutics' innovative TORPEDO platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772619726083 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs—protein degraders—for the treatment of cancer. Its future depends on the success of its platform and clinical trials. The overall investment climate, which can be assessed from this chart, determines the availability of funding for such cutting-edge and risky scientific approaches.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619726133 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - C4 Therapeutics Inc.
C4 Therapeutics is a biotech pioneering targeted protein degradation—a new way to combat diseases, including cancer. The company has no commercial revenue yet. This chart reflects how investors view its cutting-edge scientific platform, which has the potential to create an entirely new class of drugs.
P/S market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs called "degraders," which harness the body's natural defenses to destroy disease-causing proteins. This chart shows the average valuation in the sector, helping to understand the market premium placed on this innovative scientific platform.
P/S of the market as a whole
C4 Therapeutics is a biotech pioneering the field of targeted protein degradation. This new technology enables the destruction of disease-causing proteins previously thought to be untreatable. This market valuation chart helps understand the premium investors are paying for this potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company C4 Therapeutics Inc.
C4 Therapeutics is a biotech company developing a new class of drugs that target disease-causing proteins. Without revenue, it is valued based on its future potential. This chart reflects investors' faith in its innovative scientific platform and its future commercial success.
%20P%2FS%20C4%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-C4-Therapeutics-Inc.&v=1772619726406 "The graph of the company's future (projected) P/S C4 Therapeutics Inc.")
Future (projected) P/S of the market segment - Oncology targeted therapy
C4 Therapeutics is a biopharmaceutical company pioneering the development of a new class of drugs called protein degraders (PROTACs). This chart compares market expectations for its future revenue with other oncology companies. This valuation reflects investor confidence in its breakthrough technology for targeting cancer-causing proteins.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772619726458 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs that target cancer-causing proteins. This is cutting-edge science. Market optimism, evident in this chart, is vital for C4, as it provides access to the capital needed to advance this revolutionary, yet risky, technology through clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619726497 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales C4 Therapeutics Inc.
C4 Therapeutics is a biotech company developing a new class of drugs that target disease-causing proteins. Currently in the clinical stage, its revenue is generated through upfront and milestone payments from major pharmaceutical partners. The chart shows the funding supporting the development of this innovative therapeutic platform.
Sales of companies in the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs called "protein degraders." This technology allows for the destruction of disease-causing proteins, rather than simply blocking them. Currently, revenue is generated from partnerships. This chart shows investor interest in cutting-edge oncology platforms, of which C4T is a leader.
Overall market sales
C4 Therapeutics is a biotech company developing a new class of drugs that "destroy" disease-causing proteins. Its future depends on the success of this innovative platform in clinical trials. The connection to this graph is indirect—through the impact of the general economy on the availability of venture capital for funding science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company C4 Therapeutics Inc.
C4 Therapeutics is a biotech company developing a new class of drugs called "protein degraders." This technology targets cancer-causing proteins previously considered drug-resistant. This chart reflects analysts' confidence in the potential of this innovative platform and its clinical candidates.
%20sales%20of%20the%20company%20C4%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-C4-Therapeutics-Inc.&v=1772619726608 "Schedule of future (projected) sales of the company C4 Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
C4 Therapeutics is developing a new class of drugs that utilize the body's natural mechanism to "destroy" disease-causing proteins. This chart shows the overall outlook for the targeted oncotherapy sector. It allows us to assess the potential of this innovative platform and how its clinical successes compare to overall drug development trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772619726621 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
C4 Therapeutics is a biotech company developing a new class of drugs (protein degraders) for the treatment of cancer. This chart, reflecting the investment climate in biotech, is critically important. Developing such an innovative platform requires significant investment, and C4's ability to attract capital depends directly on investor confidence in the future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619726626 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality C4 Therapeutics Inc.
C4 Therapeutics is a pioneer in developing a new class of drugs called protein degraders for the treatment of cancer and other diseases. The company's business is at the forefront of science and requires significant investment in R&D. This chart illustrates the research expenditures that form the foundation for the development of potentially revolutionary drugs.
Market segment marginality - Oncology targeted therapy
C4 Therapeutics is a pioneer in targeted protein degradation—a new way to combat diseases, including cancer. Their platform allows for the "tagging" of disease-causing proteins for cellular destruction. This chart reflects the intensity of investment in this cutting-edge science, which has the potential to become a new pillar in oncology and deliver high returns in the future.
Market marginality as a whole
C4 Therapeutics is a biotech company pioneering the development of a new class of drugs that utilize the body's natural system to destroy disease-causing proteins (degradation). The overall picture of profitability is irrelevant to them. Their value lies in the potential of their scientific platform. Success depends on proof of concept in the clinic.
Employees in the company, segment and market as a whole
Number of employees in the company C4 Therapeutics Inc.
C4 Therapeutics is a biotech company pioneering targeted protein degradation for cancer treatment. This graph shows its growing team of scientists. This expansion directly reflects the company's progress in clinical programs and investment in this emerging and promising area of oncology.
Share of the company's employees C4 Therapeutics Inc. within the market segment - Oncology targeted therapy
C4 Therapeutics is a pioneer in developing a new class of drugs called degraders, which harness the body's natural defenses to destroy disease-causing proteins. This chart shows the percentage of leading scientists the company has attracted in this cutting-edge field. It's a testament to its scientific leadership and the team's commitment to breaking new ground in cancer treatment.
Number of employees in the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company pioneering targeted protein degradation for the development of new cancer drugs. The chart shows the growth in employment in this cutting-edge biotech field. The increase in the number of scientists reflects progress in developing this innovative platform, which is opening up new ways to fight the disease.
Number of employees in the market as a whole
C4 Therapeutics uses a new technology for targeted protein cleavage to create cancer drugs. This is a fundamentally new approach in pharmacology. This chart, illustrating the overall job market, shows pioneering biotech companies like C4 at the cutting edge of science, creating unique jobs for scientists shaping the future of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company C4 Therapeutics Inc. (CCCC)
C4 Therapeutics, Inc. is a biotech company developing a new class of drugs that harness the body's natural system to destroy disease-causing proteins. Its valuation is based on the potential of this innovative platform. This chart demonstrates an extremely high market capitalization per employee, as investors are betting on scientific breakthroughs from a small team.
%20of%20the%20company%20C4%20Therapeutics%20Inc.%20(CCCC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-C4-Therapeutics-Inc.-CCCC&v=1772619726876 "Chart of market capitalization per employee (in thousands of dollars) of the company C4 Therapeutics Inc. (CCCC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
C4 Therapeutics is a biotech company developing a new generation of targeted drugs that destroy cancer-causing proteins. This metric reflects investors' faith in the revolutionary potential of its TORPEDO platform. The chart shows the enormous premium the market places on the contribution of each scientist to the development of this new class of drugs.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772619727005 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
C4 Therapeutics is a biotech pioneering targeted protein degradation, a new approach to cancer treatment. This chart shows a very high market value per employee, reflecting investors' faith in the potential of their revolutionary scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619727045 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company C4 Therapeutics Inc. (CCCC)
C4 Therapeutics (CCCC) is a biotech company developing a new generation of drugs—targeted protein degradation—for the treatment of cancer. This is cutting-edge R&D. This chart shows the "cost" of this innovative platform: it measures the negative profit (expense) per scientist.
%20Chart%20C4%20Therapeutics%20Inc.%20(CCCC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-C4-Therapeutics-Inc.-CCCC&v=1772619727099 "Company Profit Per Employee (in thousands of dollars) Chart C4 Therapeutics Inc. (CCCC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
C4 Therapeutics (CCCC) is a pioneer in the field of "targeted protein degradation." They create molecules that cause cells to "eject" cancer-causing proteins. This graph shows the benchmark performance of their biotech team. It is important for assessing how effectively C4's scientific team is using their innovative platform.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772619727134 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
C4 Therapeutics (CCCC) is a biotech company developing a new generation of drugs that utilize a "protein targeted degradation accelerator" (PROTAC) mechanism to destroy disease-causing proteins. This is cutting-edge science. The chart shows the enormous R&D costs (negative profit) per scientist in the effort to create this new class of drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619727203 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee C4 Therapeutics Inc. (CCCC)
C4 Therapeutics is a biotech company developing a new class of drugs that exploit protein degradation mechanisms to fight cancer. This chart reflects its focus on science. The lack of revenue per employee is typical for an early-stage company investing all its resources into validating its innovative platform in clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-C4-Therapeutics-Inc.-CCCC&v=1772619727245 "Sales chart per company employee C4 Therapeutics Inc. (CCCC)")
Sales per employee in the market segment - Oncology targeted therapy
C4 Therapeutics (CCCC) is a biotech company specializing in targeted protein degradation (TPD). They create molecules that "destroy" cancer-causing proteins. This graph shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their cutting-edge R&D platform.
Sales per employee for the market as a whole
C4 Therapeutics (CCCC) is a biotech company pioneering the field of "targeted protein degradation." Their technology forces cells to "destroy" disease-causing proteins. They are a clinical-stage R&D company. This graph (close to zero) shows their investment in research: the company has no revenue, but they have a staff of scientists working on this breakthrough platform.
Short shares by company, segment and market as a whole
Shares shorted by company C4 Therapeutics Inc. (CCCC)
C4 Therapeutics is a biotech company developing a new class of drugs—protein disruptors (PROTACs)—targeted for cancer treatment. This chart shows bearish bets. The shorts are driven by the high risks of the new technology. Investors are betting that the platform will prove ineffective or toxic in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-C4-Therapeutics-Inc.-CCCC&v=1772619727339 "Short Shares Chart for the Company C4 Therapeutics Inc. (CCCC)")
Shares shorted by market segment - Oncology targeted therapy
C4 Therapeutics (CCCC) is a clinical-stage biotech developing a new generation of drugs (protein degraders) for the treatment of cancer. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting the sector, they don't believe risky R&D will succeed. For C4, which relies on capital, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
C4 Therapeutics (CCCC) is a clinical-stage biotech developing a new generation of targeted cancer therapy (protein degradation). This is cutting-edge, but risky science. This market pessimism chart shows when investors are unwilling to "buy the science." CCCC shares, lacking revenue, sell off during periods of panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator C4 Therapeutics Inc. (CCCC)
C4 Therapeutics is a clinical-stage biotech pioneering protein degradation for cancer treatment. The stock is highly speculative. This chart can surge above 70 on positive R&D news or technology hype. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-C4-Therapeutics-Inc.-CCCC&v=1772619727441 "RSI 14 indicator chart for the company's stock C4 Therapeutics Inc. (CCCC)")
RSI 14 Market Segment - Oncology targeted therapy
C4 Therapeutics is at the forefront of science, developing protein degraders (PROTACs)—a new way to destroy cancer cells previously considered untreatable. This chart shows the overall "temperature" in the volatile targeted oncotherapy sector. It helps separate investor reactions to C4's clinical data from the general "hype" or "disappointment" that has gripped this entire biotech niche.
RSI 14 for the overall market
C4 Therapeutics (CCCC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CCCC (C4 Therapeutics Inc.)
C4 Therapeutics is a biotech company developing drugs using protein targeting and abrasion control (PROTAC) technology for the treatment of cancer. This chart shows the average target price. Analysts' estimates are based on early clinical data and the potential of their platform to target cancer proteins.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CCCC-C4-Therapeutics-Inc.&v=1772619727670 "A chart showing analyst consensus forecasts for the expected stock price. CCCC (C4 Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price CCCC (C4 Therapeutics Inc.)
C4 Therapeutics (CCCC) is a biotech company specializing in protein degradation products (PROTACs), a new way to destroy diseased proteins that cause cancer. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their cutting-edge scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CCCC-C4-Therapeutics-Inc.&v=1772619727850 "A chart showing the difference between the consensus forecast and the actual stock price. CCCC (C4 Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
C4 Therapeutics (CCCC) is a biotech company pioneering the field of "protein targeted therapy" (PROTAC). Their drugs don't block the protein that causes cancer, but rather "destroy" it. This chart shows general expectations for the targeted oncology sector, reflecting experts' confidence in this new treatment modality.
Analysts' consensus forecast for the overall market share price
C4 Therapeutics (CCCC) is a biotech pioneering the development of protein "degraders" (similar to Arvinas) aimed at destroying cancer-causing proteins. This chart shows the overall "risk appetite." For CCCC, which is working on a revolutionary technology, overall market optimism (a rising chart) is critical to funding lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index C4 Therapeutics Inc.
C4 Therapeutics (CCCC) is a biotech pioneer working in the field of targeted protein degradation (TPD), like Arvinas. Their platform (TORPEDO) creates a molecular glue that targets cancer-causing proteins for destruction. This chart is a clear indicator of faith in their R&D platform. It reflects the market's assessment of their clinical data and their ability to compete in this hot scientific field.
AKIMA Market Segment Index - Oncology targeted therapy
C4 Therapeutics uses its targeted protein cleavage (TPD) approach to develop a new class of cancer drugs. This chart shows the average index for the targeted therapy sector. It provides investors with a benchmark for how C4's innovative, yet early-stage platform compares to the sector average.
The AKIM Index for the overall market
C4 Therapeutics is a biotech company pioneering targeted protein degradation (TPD). It develops degraders for cancer treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative platform, which aims to destroy disease-causing proteins, compares to overall economic trends in biotech.
